Member Info for Dazpink

Https://hemogenyx.com/wp-content/uploads/2026/06/273758-Hemogenyx-AGM-Notice.pdf

Soon be AGM, 30 June 2026 at 2 p.m. BST

The business we will discuss at the AGM is made up of resolutions that are regularly brought to Shareholders. The formal notice of AGM and the Resolutions to be proposed at the AGM are set out on page 6 of this document. The following is a brief summary of the items of business:

• Resolution 1 relates to the receipt and adoption of the Company’s annual accounts for the financial year ended

31 December 2025 together with the directors’ reports and auditor’s report (the “2025 Annual Report and

Accounts”) on those accounts;

• Resolution 2 relates to the approval of the Directors’ Remuneration Report which is set out in the 2025 Annual

Report and Accounts;

• Resolution 3 relates to the re-appointment of the auditors;

• Resolution 4 authorises the Audit Committee to agree the auditor’s remuneration;

• Resolution 5 relates to the re-appointment as Director of Vladislav Sandler, as set out in Article 74.1 of the

Articles of Association of the Company;

• Resolution 6 relates to the re-appointment as Director of Alexis Sandler, as set out in Article 74.1 of the Articles

of Association of the Company;

• Resolution 7 relates to the re-appointment as Director of Sir Marc Feldmann. Whilst not necessary under the

Company’s Articles of Association, Principle 6 of the New QCA Corporate Governance Code 2023 (the “QCA

Code”) provides that, for companies that have adopted the QCA Code, as a matter of best practice, and not a

legal requirement, all board members should submit themselves for re-election on an annual basis;

• Resolution 8 relates to the re-appointment as Director of Peter Redmond, who retires in accordance with

Principle 6 of the QCA Corporate Governance Code and offers himself for re-appointment;

• Resolution 9 relates to the Directors’ authority to allot shares;

• Resolution 10 relates to the disapplication of pre-emption rights; and

• Resolution 11 relates to the Directors’ authority to call a general meeting (other than an annual general

meeting) of the Company on a 14 clear days’ notice period.

Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months

The U.S. Food and Drug Administration (FDA) is announcing actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials. The FDA’s work is outlined in Operation TrialBlazer, a U.S. Department of Health and Human Services (HHS) initiative.

The FDA is committed to ensuring the United States remains the global standard for pharmaceutical innovation and regulatory rigor for the benefit of American patients and innovators. The agency is eliminating unnecessary regulatory burden, clarifying phase-appropriate requirements, and building partnerships with government, academic medical centers and the private sector.

Just shows you how crazy it is, the share price back in August 2025 was $34, today trading at $166 which will increa more if it decides to sell

In November 2023 it was rading at $18, this is why we hold Hemo in the belief that we could just hit similar values

Sought-after biotech company pushes back against being scooped up following Merck’s unsuccessful $32bn bid

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://help.ft.com/faq/gifting-and-sharing-an-article/what-is-a-gift-article/.

https://www.ft.com/content/3b1e5908-1cf4-4cc8-ade2-f0636a90739c?syn-25a6b1a6=1

One of the world’s most sought-after biotech companies said getting acquired by a large pharmaceutical group was “not an area of high priority” after delivering groundbreaking clinical trial results in pancreatic cancer treatment.

Treatment with daraxonrasib, an experimental drug developed by US company Revolution Medicines, led to “significantly longer overall survival and progression-free survival than chemotherapy” for patients living with pancreatic cancer, according to the results of a final stage trial published recently in the New England Journal of Medicine.

The drug, taken daily through three pills, targets a cellular protein known as KRAS which is responsible for almost all pancreatic cancers and has been hailed as the most promising advancement in oncology in almost two decades. Developing a treatment to target KRAS was previously thought to be beyond the reach of science.

Daraxonrasib’s potential, which is currently being evaluated by the US Food and Drug Administration, has catapulted Revolution to the attention of larger groups including Merck, which made an ultimately unsuccessful bid of about $32bn in January.

https://www.ft.com/content/3b1e5908-1cf4-4cc8-ade2-f0636a90739c?syn-25a6b1a6=1

AI

Patient P4’s treatment with Hemogenyx Pharmaceuticals’ HG-CT-1 (a CAR-T therapy) is imminent. While the company has not announced an exact calendar date, investor expectations and clinical updates point to a near-term rollout in June 2026 as part of the new dose-escalation and pediatric arms of the trial.Hemogenyx confirmed they had initiated patient enrolment and had escalated to the next dose level. The exact drop date of the Regulatory News Service (RNS) depends on enrollment progress at MD Anderson Cancer Center and clinical manufacturing completion.

PureTech Health can raise non-dilutive capital to fund share buybacks by monetising its unique "hub-and-spoke" model Investors back Seaport IPO in tentative return for biotech listings, rather than relying on dilutive public share offerings. PureTech has a history of executing this strategy.

Agree Jose, this is why even though funding is in place he doesnt want to release it formally to the market.

He will use thhe money obtained from Seaport IPO to buy back shares shortly

Puretech did this in 2022 & 2024

The latest authorization permits the company to purchase up to 24,341,819 ordinary shares. This represents 10% of the company’s total voting right share capital (excluding treasury shares) as of the late-April publication date

I am ignoring the current share price, we know things are moving in the right direction and when companies reach phase 3 stage usually a big pharma purchasing it.

The thing most pleasing is that Celea Therapeutics has reached phase 2, its next milestone is phase 3, it has already informed us that it has secured substantial non-binding commitments from external investors to fund its upcoming Phase 3 SURPASS-IPF trial.

The fundraising is considered substantially complete, with Celea targeting to formally close the financing in early Q3 2026

The Phase 3 trial is expected to commence in close proximity to the official closing of the financing round.

Key Trial Details

*Trial Name: SURPASS-IPFTrial Design: Global, randomized, double-blind, head-to-head trial

*Intervention: Deupirfenidone (825 mg dosed three times daily) versus pirfenidone (801 mg dosed three times daily)

*Timeline: Initiated to begin in the first half of 2026

*Pathway: The trial is designed to act as the basis for potential registration via a streamlined FDA 505(b)(2) pathway.

Fingers crossed we get something like this

GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with two late-stage assets the drugmaker believes have “multi-blockbuster potential”.

The all-cash transaction sees GSK pay $124 per share of Nuvalent, representing a 40% premium to the US-listed biotech’s last closing price of $88.49. The British drugmaker will fund the deal through new and existing debt facilities plus cash, with no resulting change to its full-year guidance.

The high-value deal – second only in GSK’s history to a $20bn asset swap with Novartis in 2015 – marks a change in tack from new CEO Luke Miels. Since taking over from Emma Walmsley in January, Miels has largely conducted “bolt-on” acquisitions and licensing deals to reinforce the company’s pipeline.

Fingers crossed we get something like this

GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with two late-stage assets the drugmaker believes have “multi-blockbuster potential”.

The all-cash transaction sees GSK pay $124 per share of Nuvalent, representing a 40% premium to the US-listed biotech’s last closing price of $88.49. The British drugmaker will fund the deal through new and existing debt facilities plus cash, with no resulting change to its full-year guidance.

The high-value deal – second only in GSK’s history to a $20bn asset swap with Novartis in 2015 – marks a change in tack from new CEO Luke Miels. Since taking over from Emma Walmsley in January, Miels has largely conducted “bolt-on” acquisitions and licensing deals to reinforce the company’s pipeline.

GSK doubles down on oncology with $10.6bn Nuvalent takeover

Nuvalent’s two late-stage lung cancer assets – zidesamtinib and neladalkib – are currently under FDA review.

https://www.pharmaceutical-technology.com/news/gsk-doubles-down-on-oncology-with-10-6bn-nuvalent-takeover/

GSK doubles down on oncology with $10.6bn Nuvalent takeover

Nuvalent’s two late-stage lung cancer assets – zidesamtinib and neladalkib – are currently under FDA review.

https://www.pharmaceutical-technology.com/news/gsk-doubles-down-on-oncology-with-10-6bn-nuvalent-takeover/

Https://www.pharmexec.com/view/roundup-incyte-acquire-vega-therapeutics-galmed-colospan-johnson

Https://www.pharmexec.com/view/roundup-incyte-acquire-vega-therapeutics-galmed-colospan-johnson

Another large deal

https://www.ft.com/content/a438f9c6-22bd-4dd3-967e-007c95d64d37?syn-25a6b1a6=1

Another large deal

https://www.ft.com/content/a438f9c6-22bd-4dd3-967e-007c95d64d37?syn-25a6b1a6=1

Thanks Frank, looks very promising, things are getting ramped up, seaport, celea and Gallop are on track to give puretech a well deserved Booom in the share price over the next 6 - 9 months

Intresting article last month about puretech, Eric Elenko Says PureTech Turned $18.5 Million Into $1.1 Billion by Fixing Big Pharma's Castoffs

https://finance.biggo.com/news/fe8c9bd942c4ed51